Raliva

Raliva is a Swiss clinical-stage biopharmaceutical company dedicated to the development of innovative, long-acting analgesic therapies for post-operative recovery. The company's lead candidate, RAL-101, is a proprietary formulation of bupivacaine designed to provide extended pain relief and significantly reduce the clinical requirement for post-surgical opioids. By utilizing a specialized drug delivery platform, Raliva optimizes the release kinetics of established small molecule agents to improve patient outcomes. The company was founded by industry veterans with extensive experience in the analgesic and drug delivery sectors. Raliva is currently advancing its clinical programs to address the global unmet need for effective, non-addictive pain management solutions.